RN

Rishabh Neb

Active Director Director DIN 08098821
DIN 08098821 First appointment Dec 2017 Primary industry Healthcare
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Dec 2017
Shareholding value •••• Premium profile

About Rishabh Neb

Data last updated:

Rishabh Neb is a Director at Nebreca Pharma Private Limited (since 2017). The company operates in Healthcare. Nebreca Pharma Private Limited reported revenue of ₹2,938 (FY 2025).

DIN 08098821
Primary Designation Director
Industry Healthcare
First Appointment 21 Dec 2017
Oldest Company Age 22 yrs
Largest company Nebreca Pharma Private Limited · ₹2,938 (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Nebreca Pharma Private Limited U51397UP2004PTC028410
Director21 Dec 20172004₹2,938 (FY 2025)Active

Board colleagues of Rishabh Neb

NameDINCompanyDesignation
Anubhuti Neb05180431Nebreca Pharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Nebreca Pharma Private Limited
Premium access

Shareholding and investment profile for Rishabh Neb

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rishabh Neb

Rishabh Neb currently holds 1 directorship: Nebreca Pharma Private Limited (Director, since 21 Dec 2017, revenue ₹2,938 (FY 2025)).

Rishabh Neb was first appointed on 21 Dec 2017 as Director at Nebreca Pharma Private Limited.

The current boards of Rishabh Neb's companies include Anubhuti Neb (Nebreca Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available